Drug-drug interaction study of SMP-508 and sitagliptin.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221771

Enrollment

Registered

2012-04-19

Start date

2012-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

investigational material(s) Generic name etc : SMP-508 (repaglinide) INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Subject Healthy adult male volunteers Inclusion criteria - Subjects who provided written informed consent to participate in the study. - Subjects whose body weight are between 50.0 and 80.0 kg and whose body mass index (BMI) are 18.5 to 25.0 {BMI = body weight (kg) / [height (m)]2} etc.

Exclusion criteria

Exclusion criteria: Exclusion criteria - Subjects with a history of drug allergies. - Subjects with any alcohol abuse. etc

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics To assess the pharmacokinetics of SMP-508 or sitagliptin given in co-administration and .single administration.	—

Secondary

Measure	Time frame
Safety To investigate the safety of co-administration of SMP-508 and sitagliptin.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026